AI MARKET SCANNING

Zentalis Pharmaceuticals Inc

📅 Next Catalyst: Nov 10, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Health Technology 🏭 Biotechnology
AVG HISTORICAL GAP +0.05%
MAX GAP RECORD +9.97%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ZNTL
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 10, 2026 Earnings Release 2026-11-10 (AFTER CLOSE (21:00)) 🔮 UPCOMING 🔒
Aug 06, 2026 Earnings Release 2026-08-06 (AFTER CLOSE)
-6.40%
Mar 26, 2026 Earnings Release 2026-03-26 (AFTER CLOSE)
-2.62%
Nov 10, 2025 Earnings Release 2025-11-10 (AFTER CLOSE)
-5.30%
Aug 06, 2025 Earnings Release 2025-08-06 (AFTER CLOSE)
+0.72%
May 14, 2025 Earnings Release 2025-05-14 (AFTER CLOSE)
+4.20%
Mar 26, 2025 Earnings Release 2025-03-26 (BEFORE OPEN)
-1.07%
Nov 12, 2024 Earnings Release 2024-11-12 (AFTER CLOSE)
+9.97%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.1%
Bullish Gaps (5)
Bearish Gaps (6)
Neutral / Flat (1)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ZNTL

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Zentalis Pharmaceuticals, Inc. is a clinical oncology innovator developing an oral, non-chemotherapy, biomarker-driven treatment approach for ovarian cancer and multiple tumor types. The therapeutics development and biomarker expertise is advancing monotherapy and combination studies of its investigational potential first-in-class WEE1 inhibitor, azenosertib. It is focused on translating WEE1 science into…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗